Sildalis

Basic Sildalis Information

• INN (International Nonproprietary Name): Sildalis does not have an official INN; it is a combination medication containing sildenafil citrate (INN: sildenafil) and tadalafil (INN: tadalafil).
• Brand Names Available In United Kingdom: Sildalis is marketed as a non‑innovator, mostly internet‑sold combination product that merges the active ingredients found in Viagra (sildenafil) and Cialis (tadalafil); it is primarily available through online pharmacies and unofficial distributors rather than registered UK high‑street chains.
• ATC Code: G04BE03 for sildenafil and G04BE08 for tadalafil, indicating drugs used in erectile dysfunction within the genito‑urinary system classification.
• Forms & Dosages: Sildalis tablets typically contain 100mg sildenafil + 20mg tadalafil and are sold in blister packs of approximately 6–20 tablets.
• Manufacturers In United Kingdom: Sildalis is not produced by major originator manufacturers in the UK; manufacturing is mostly by Indian generic companies or direct‑to‑web suppliers and it is not supplied through standard UK pharmaceutical supply chains.
• Registration Status In United Kingdom: Not registered with the MHRA as a fixed combination product; there is no public MHRA listing for Sildalis.
• OTC / Rx Classification: Components are generally prescription‑only medicines in the UK; Sildalis itself is effectively treated as prescription‑only and is commonly sold without prescription through unregulated online channels.

Critical Warnings & Restrictions

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

Sildalis contains two PDE5 inhibitors: sildenafil 100 mg plus tadalafil 20 mg, and the combination is not registered with the MHRA, which means it lacks UK regulatory safety assurances.

This elevates risk for elderly patients and those with cardiovascular, hepatic or renal disease because dose guidance for the combined product is not established.

Absolute contraindications include concurrent nitrates, use of riociguat, known allergy to sildenafil or tadalafil, and unstable cardiac disease that makes sexual activity unsafe.

Use extreme caution and seek clinician review if you have had a recent stroke, myocardial infarction, or uncontrolled hypotension because additive haemodynamic effects may be hazardous.

• Absolute Contraindications: Concurrent nitrates (eg nitroglycerin), riociguat, allergy to sildenafil/tadalafil, unstable cardiovascular disease preventing sexual activity.
• Relative Contraindications / Cautions: Significant hepatic or renal impairment, frail elderly with cardiovascular risk, recent stroke or myocardial infarction, retinitis pigmentosa, concurrent potent CYP3A4 inhibitors.

• Urgent Symptoms Checklist:
• Chest pain or chest pressure.
• Fainting or sudden syncope.
• Painful erection lasting longer than four hours (priapism).

For any severe adverse event, seek immediate GP advice or attend A&E without delay.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Sildenafil and tadalafil can cause dizziness, blurred or blue‑tinted vision, and syncope, which may impair driving or operating machinery.

UK driving law requires drivers to be able to drive safely and to report persistent visual loss or fainting to the DVLA.

• Do Not Drive If…
• You experience dizziness after taking the medication.
• You have blurred or blue‑tinted vision following a dose.
• You suffer fainting or delayed reaction times.

• Legal Responsibilities: DVLA Reporting: Report persistent vision loss or blackout episodes to your GP and the DVLA as required.
• Employer Notification: If your job requires high alertness (driving, heavy machinery), inform your employer and avoid safety‑critical duties while affected.

Q&A — Can I Drive After Taking It In The UK?

If you experience dizziness, blurred or blue‑tinted vision, fainting or delayed reactions after taking Sildalis, do not drive.

If you are asymptomatic, driving is generally permitted, but you must meet DVLA fitness‑to‑drive standards and report persistent vision loss or syncope to your GP and the DVLA.

Usage Basics

INN, Brand Names Available In The UK

The product Sildalis has no official INN; it is a fixed combination of two INNs: sildenafil and tadalafil.

Brand‑name equivalents for the single agents are Viagra for sildenafil and Cialis for tadalafil, both of which are widely known in the UK.

• INN: International Nonproprietary Name denotes the generic drug name, for example sildenafil.
• Brand: The commercial name used by originator companies, for example Viagra or Cialis.

Legal Classification (POM, P, GSL)

• Both sildenafil and tadalafil are prescription‑only medicines (POM) in the UK, although specific pharmacist‑supplied options exist for sildenafil (Viagra Connect).
• A combined product such as Sildalis is not MHRA‑approved and should be treated as POM; purchasing from unregulated vendors circumvents UK safety checks.

• Legal Pathways:
• NHS prescription supplied via GP or sexual health clinic.
• Private prescription from a GP or sexual health clinic.
• Pharmacist supply for specific licensed products (eg Viagra Connect 50mg after consultation).

• Checklist To Verify A Pharmacy:
• Look for a valid GPhC registration number on the website or in‑store.
• Confirm a UK business address and contact details.
• Ensure prescription checks and pharmacist consultations are offered before supply.

Dosing Guide

Standard Regimens (NHS Guidelines)

Published product information for Sildalis sold online typically lists one tablet containing 100mg sildenafil + 20mg tadalafil taken 30–60 minutes before sexual activity, not more than once per 24 hours.

NHS and licensed practice usually favour established monotherapies with set dosing ranges: sildenafil typically 25–100mg as required, tadalafil 5–20mg as required or 2.5–5mg daily for continuous use.

Because Sildalis combines both agents at substantial strengths, there is potential for amplified adverse effects compared with single agents.

• Comparison:
• Sildalis (listed online): 100mg sildenafil + 20mg tadalafil, one tablet before sexual activity.
• Licensed sildenafil: 25–100mg as required; pharmacist‑supply option at 50mg for Viagra Connect.
• Licensed tadalafil: 5–20mg as required or 2.5–5mg daily for ongoing benefit.

• Checklist To Discuss Dose With A Prescriber:
• Review cardiovascular history and nitrate use.
• Assess current medicines for CYP3A4 interactions.
• Consider liver or kidney function and age‑related dose reductions.

Adjustments For Comorbidities

Sildalis has not been formally studied in hepatic or renal impairment and therefore lacks explicit dose recommendations for these populations.

For the individual agents, lower starting doses are recommended in significant liver or kidney disease and in frail elderly patients because clearance may be reduced.

Avoid or reduce dose when co‑administered with strong CYP3A4 inhibitors such as some azole antifungals or macrolide antibiotics, and monitor blood pressure when given with antihypertensives.

• Checklist For Dose Adjustments:
• Consider lower starting dose in elderly and those with hepatic or renal impairment.
• Review interacting medications and consider dose reduction when on CYP3A4 inhibitors.
• Monitor for hypotension if used with alpha‑blockers or multiple antihypertensives.

• Interacting Drug Classes:
• Potent CYP3A4 inhibitors (eg certain azoles, macrolides).
• Nitrates and nitrate donors.
• Riociguat (guanylate cyclase stimulator).

Q&A — What If I Miss A Dose?

Sildalis is taken as needed and a missed dose is not applicable.

Do not double up doses within 24 hours.

If you accidentally take more than intended, seek urgent medical advice because overdose risks include severe hypotension and priapism.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

Alcohol can increase dizziness and may reduce erectile function; combined use with PDE5 inhibitors raises the risk of symptomatic hypotension.

Large or fatty meals can delay the onset of sildenafil; tadalafil is less affected by food.

Caffeine has minimal direct interaction but may add to jitteriness and increase the chance of perceived side effects.

• Quick Rules:
• Avoid heavy drinking when planning to use PDE5 inhibitors.
• Consider timing sildenafil away from large, fatty meals for faster onset.

Common Drug Conflicts (MHRA Yellow Card Data)

Major interactions include nitrates (life‑threatening hypotension), riociguat (contraindicated), alpha‑blockers (orthostatic hypotension risk), potent CYP3A4 inhibitors (raise PDE5 levels) and some antihypertensives.

• Checklist To Tell Your Pharmacist/GP:
• All prescription and over‑the‑counter medicines you take.
• Any nitrates or recreational nitrite use (eg “poppers”).
• Herbal supplements and recent antibiotics or antifungals.

User Reports & Trends

Online search interest for sildalis often reflects demand for a perceived “enhanced potency” dual‑action product.

Patient forums and NHS Choices threads report a mix of positive anecdotes about stronger effects and frequent complaints of headaches, flushing and visual disturbances.

Clinician commentary online stresses the lack of regulatory oversight and recommends licensed alternatives instead of unsupervised combination therapy.

• Common Patient‑Reported Effects:
• Perceived increased efficacy compared with single agents.
• More frequent headaches and flushing.
• Incidental visual disturbances and dizziness reported more often than with monotherapy.

• Checklist For Assessing Online Seller Trustworthiness:
• Look for a registered pharmacy logo and a valid GPhC number.
• Prefer sellers that require a prescription or provide regulated e‑consultation.
• Avoid sites offering Sildalis without any prescription checks or with shipping from overseas only.

Real data indicates Sildalis is primarily distributed online and commonly manufactured by Indian generics or direct‑to‑web suppliers rather than licensed UK manufacturers.

Access & Purchase Options

Boots, LloydsPharmacy, Superdrug

High‑street chains supply licensed sildenafil and tadalafil products via private prescription or pharmacy supply models such as pharmacist consultation for Viagra Connect.

Sildalis itself is generally not stocked by major UK chains because it lacks MHRA approval and standard supply routes.

• In‑Store Routes:
• Pharmacist consultation and pharmacist‑supplied products where appropriate.
• Private prescription drop‑offs to pharmacy dispensaries.
• Online services run by registered UK chains offering e‑prescribing and local collection.

• Checklist To Verify A UK‑Registered Pharmacy:
• Check the General Pharmaceutical Council (GPhC) number on the website or in store.
• Confirm a UK address and NHS contact options.

Online Pharmacies And NHS E‑Prescriptions

UK patients can obtain prescriptions via the NHS, private GPs, or regulated online pharmacies that issue e‑prescriptions and supply to local pharmacies.

Unregulated overseas online retailers commonly sell Sildalis without prescription, bypassing MHRA safety checks and posing safety risks.

In our online pharmacy, sildalis is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Mechanism & Pharmacology

Simplified Explanation

Sildenafil and tadalafil are phosphodiesterase type 5 (PDE5) inhibitors that enhance nitric oxide–mediated vasodilation in penile tissue and improve erections in response to sexual stimulation.

Sildenafil typically has an onset of around 30–60 minutes and a duration of about 4–6 hours.

Tadalafil has a longer duration—up to 36 hours—and is associated with muscle and back pain in some patients.

• PDE5: Enzyme that breaks down cyclic GMP; inhibition increases blood flow to penile tissue.
• Half‑Life: The time taken for plasma concentration to reduce by half; sildenafil is shorter, tadalafil is longer.
• Onset / Duration: Sildenafil onset ~30–60 mins, duration ~4–6 hours; tadalafil onset similar but duration up to ~36 hours.

Clinical Terms

Pharmacokinetic and pharmacodynamic overlap can produce amplified hypotensive responses and cumulative side effects when both agents are combined.

Because Sildalis has not been adequately studied, additive effects cannot be reliably predicted, dosed, or reversed.

• Sildenafil Vs Tadalafil:
• Sildenafil: shorter duration, more commonly associated with transient visual disturbance.
• Tadalafil: longer duration, may cause myalgia and back pain.
• Combination: theoretical immediate and prolonged effect but higher cumulative exposure and risk.

Indications & Off‑Label Uses

MHRA‑Approved Uses

• Sildenafil Licensed Uses: Erectile dysfunction and pulmonary arterial hypertension in specialised formulations.
• Tadalafil Licensed Uses: Erectile dysfunction, benign prostatic hyperplasia (BPH) and in certain formulations pulmonary arterial hypertension.
• Sildalis as a fixed combination has no MHRA approval and no officially sanctioned indication in the UK.

Off‑Label Practices In NHS And Private Care

Clinicians may sometimes prescribe PDE5 inhibitors off‑label for specific indications with informed consent and monitoring, but simultaneous combination therapy with two PDE5 inhibitors is not a standard or widely supported practice in NHS guidelines.

• Clinician Considerations For Off‑Label Prescribing:
• Evidence supporting benefit and safety.
• Documented informed consent from the patient.
• Clear monitoring plan for adverse effects and blood pressure.
• Reporting of outcomes and any adverse events.

Key Clinical Findings

There are no robust, peer‑reviewed trials establishing the safety or efficacy of a fixed combination of sildenafil plus tadalafil; regulatory records do not list any approved combination product.

Most clinical evidence supports single‑agent use: multiple randomised controlled trials have demonstrated efficacy for sildenafil and tadalafil separately in patients with erectile dysfunction.

• There are no reliable combination trials for Sildalis; safety signals and dosing guidance for the combined exposure are therefore unavailable.

Alternatives Matrix

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

• Consider expected efficacy and whether rapid onset or longer duration is desired.
• Assess your tolerance for specific side effects (visual disturbance vs myalgia).
• Review potential drug interactions and contraindications with current medicines.
• Consider cost and whether NHS prescription eligibility applies in your case.
• Think about convenience: daily low‑dose tadalafil versus as‑needed dosing.
• Engage in shared decision making with your GP or a sexual health clinic.

Common Questions

• Is Sildalis Approved In The UK? — No; there is no MHRA registration for the combination product.
• Can I Buy It Without A Prescription? — Many online sellers offer it without a prescription but this bypasses UK safety checks and is unsafe.
• Is Combination Therapy More Effective? — Anecdotal reports suggest stronger effects but there is no formal evidence and side‑effect burden is likely increased.
• What Should I Do If I Get Side Effects? — Stop the medicine and seek advice from a GP or pharmacist; attend A&E for severe events such as chest pain, syncope or priapism lasting more than four hours.

• If You Experience… (Urgent Checklist):
• Chest pain or pressure — go to A&E immediately.
• Syncope or fainting — seek urgent medical review.
• Erection >4 hours — attend A&E or urgent care to avoid tissue damage.

NHS Cost & Access Comparison Table

Prescription charges apply per item in England; prescriptions are free in Scotland, Wales and Northern Ireland.

Private costs for branded Viagra or Cialis vary considerably between pharmacies and depend on whether a private consultation fee is charged.

Sildalis bought overseas may appear cheaper but lacks UK safety assurance and pharmacovigilance.

Registration & Regulation

MHRA Approval Process

The MHRA requires clinical data demonstrating quality, safety and efficacy before granting marketing authorisation for a medicinal product in the UK.

• MHRA Application Steps:
• Submission of a quality dossier including manufacturing details and batch testing.
• Clinical study data demonstrating safety and efficacy.
• Risk management plan and pharmacovigilance arrangements.
• Labeling and patient information approved for UK use.

• Checklist For Patients Buying Online:
• Verify MHRA and GPhC registration where applicable.
• Avoid sites that ship only from overseas without prescription checks.
• Keep batch and expiry details and report adverse events via the Yellow Card scheme.

NHS Prescribing Framework

• NHS Formulary: A list of medicines supported for use within the NHS, based on evidence and cost‑effectiveness.
• Private Prescription: Issued by a private prescriber and legally valid, but may not be funded by the NHS.

• Checklist For Obtaining A Safe Prescription:
• Use a face‑to‑face or regulated e‑consultation with a UK clinician.
• Ensure medication review covers cardiovascular risk and concurrent medications.
• Arrange appropriate follow‑up and reporting of adverse effects.

Storage & Handling

UK Household Storage (Cold/Damp Climate)

Store below 30°C, away from moisture and direct sunlight; a dry room‑temperature cabinet is preferred in typical UK homes to reduce humidity exposure.

Keep tablets in their original blister packaging to protect from light and to retain batch and expiry information.

Keep out of reach of children and pets.

• Home Storage Checklist:
• Temperature controlled below 30°C.
• Dry place away from bathrooms or kitchens with high humidity.
• Remain in original blister strips until use.
• Carry in hand luggage when travelling; avoid checked luggage extremes of temperature.

Guidance From NHS And Pharmacists

• Dispose of out‑of‑date or unneeded medicines via pharmacy take‑back schemes or local waste services; do not flush tablets down the toilet.
• If tablets change colour or texture or blister is broken, do not use and consult a pharmacist.

• Why Storage Matters:
• Improper storage can reduce tablet potency and affect safety.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Pharmacists should confirm a patient’s current medicines, cardiovascular history, nitrate use, liver and kidney function, vision problems, and alcohol intake before supplying PDE5 inhibitors.

Counselling points should include timing of dose, expected onset and duration, common side‑effects, and clear instructions for when to seek urgent care.

• Standard Pharmacy Counselling Script Checklist:
• Confirm identity and prescription validity.
• Ask about nitrates, riociguat and recent cardiac events.
• Explain as‑needed dosing and the 24‑hour maximum frequency.
• Advise on driving and safety‑critical work if symptoms occur.

• Must‑Ask Questions:
• Do you take nitrates or recreational nitrites?
• Have you had a recent heart attack or stroke?
• Are you taking other prescription medicines or herbal remedies?

NHS Patient Safety Advice

• Obtain licensed monotherapy where possible and use regulated pharmacies for supply.
• Report adverse events via the Yellow Card scheme and involve your GP for baseline cardiovascular assessment, especially if aged over 50 or with comorbidities.
• For persistent erectile dysfunction, arrange referral to NHS sexual health services or urology for investigation rather than relying on unregulated online products.

• Follow‑Up Actions Checklist:
• Blood pressure check and medication review.
• Consider specialist referral if ED persists despite treatment.
• Document and report any unexpected reactions.

Delivery Across United Kingdom

Final Notes

Sildalis is a non‑registered combination of sildenafil citrate 100mg and tadalafil 20mg primarily sold online by non‑innovator manufacturers and not listed by major regulators.

Physicians and pharmacists do not generally recommend combining two PDE5 inhibitors because of higher risk of adverse effects and lack of formal dosing guidance.

If you choose to pursue treatment for erectile dysfunction, seek a regulated consultation so a safe, licensed option such as sildenafil or tadalafil can be prescribed or pharmacist‑supplied where appropriate.

Report any suspected adverse reactions to the MHRA Yellow Card scheme and keep your GP informed of all medicines you take.